{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:18:40Z","timestamp":1791357520174,"version":"4.3.1"},"publisher-location":"Cham","reference-count":30,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030391409","type":"print"},{"value":"9783030391416","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/7854_2019_91","type":"book-chapter","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T10:31:03Z","timestamp":1555410663000},"page":"227-244","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Inflammation, Antipsychotic Drugs, and Evidence for Effectiveness of Anti-inflammatory Agents in Schizophrenia"],"prefix":"10.1007","author":[{"given":"Ananda K.","family":"Pandurangi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,17]]},"reference":[{"key":"91_CR1","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.schres.2011.10.026","volume":"136","author":"I Arias","year":"2012","unstructured":"Arias I, Sorlozano A, Villegas E et al (2012) Infectious agents associated with schizophrenia: a meta-analysis. Schizophr Res 136:128\u2013136","journal-title":"Schizophr Res"},{"key":"91_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1475-2891-13-91","volume":"13","author":"MA Arroll","year":"2014","unstructured":"Arroll MA, Wilder L, Neil J (2014) Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review. Nutr J 13:91","journal-title":"Nutr J"},{"issue":"9","key":"91_CR3","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1007\/s00213-015-4044-5","volume":"233","author":"D Baumeister","year":"2016","unstructured":"Baumeister D, Ciufolini S, Mondelli V (2016) Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment? Psychopharmacology (Berl) 233(9):1575\u20131589","journal-title":"Psychopharmacology (Berl)"},{"issue":"7","key":"91_CR4","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1517\/14656566.2015.1032248","volume":"16","author":"JM Bumb","year":"2015","unstructured":"Bumb JM, Enning F, Leweke FM (2015) Drug repurposing and emerging adjunctive treatments for schizophrenia. Expert Opin Pharmacother 16(7):1049\u20131067","journal-title":"Expert Opin Pharmacother"},{"key":"91_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/B978-0-12-387718-5.00005-5","volume":"101","author":"MK Chan","year":"2011","unstructured":"Chan MK, Guest PC, Levin Y et al (2011) Chapter 5 \u2013 Converging evidence of blood-based biomarkers for schizophrenia: an update. Int Rev Neurobiol 101:95\u2013144","journal-title":"Int Rev Neurobiol"},{"issue":"1","key":"91_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.intimp.2011.11.011","volume":"12","author":"ML Chen","year":"2012","unstructured":"Chen ML, Tsai TC, Wang LK et al (2012) Risperidone modulates the cytokine and chemokine release of dendritic cells and induces TNF-\u03b1-directed cell apoptosis in neutrophils. Int Immunopharmacol 12(1):197\u2013204","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"91_CR7","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/NMD.0000000000000289","volume":"203","author":"D Cox","year":"2015","unstructured":"Cox D, Chan MK, Bahn S (2015) The potential of immune biomarkers to advance personalized medicine approaches for schizophrenia. J Nerv Ment Dis 203(5):393\u2013399","journal-title":"J Nerv Ment Dis"},{"issue":"1\u20133","key":"91_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.schres.2014.02.005","volume":"154","author":"L Witte de","year":"2014","unstructured":"de Witte L, Tomasik J, Schwarz E (2014) Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment. Schizophr Res 154(1\u20133):23\u201329","journal-title":"Schizophr Res"},{"issue":"11","key":"91_CR9","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S2215-0366(18)30345-6","volume":"5","author":"B Deakin","year":"2018","unstructured":"Deakin B, Suckling J, Barnes TRE et al (2018) The benefit of minocycline (Benemin) on negative symptoms of schizophrenia with recent onset psychosis. Lancet Psychiatry 5(11):885\u2013894","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"91_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/YCO.0b013e328363b4da","volume":"26","author":"M Debnath","year":"2013","unstructured":"Debnath M, Venkatasubramanian G (2013) Recent advances in psychoneuroimmunology relevant to schizophrenia therapeutics. Curr Opin Psychiatry 26(5):433\u2013439","journal-title":"Curr Opin Psychiatry"},{"issue":"1\u20133","key":"91_CR11","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.schres.2010.06.002","volume":"121","author":"FJ Diaz","year":"2010","unstructured":"Diaz FJ, P\u00e9rez-Iglesias R, Mata I et al (2010) Possible effects of some antipsychotic drugs on C-reactive protein in a drug-na\u00efve psychotic sample. Schizophr Res 121(1\u20133):207\u2013212","journal-title":"Schizophr Res"},{"issue":"4","key":"91_CR12","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.biopsych.2013.12.002","volume":"75","author":"RR Girgis","year":"2014","unstructured":"Girgis RR, Kumar SS, Brown AS (2014) The cytokine model of schizophrenia: emerging therapeutic strategies. Biol Psychiatry 75(4):292\u2013299","journal-title":"Biol Psychiatry"},{"issue":"6","key":"91_CR13","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/npp.2017.258","volume":"43","author":"RR Girgis","year":"2017","unstructured":"Girgis RR, Ciarleglio A, Choo T et al (2017) A randomized, double-blind, placebo-controlled clinical trial of tocilizumab, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia. Neuropsychopharmacology 43(6):1317\u20131323","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"91_CR14","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1001\/jamapsychiatry.2017.3191","volume":"74","author":"FP Hartwig","year":"2017","unstructured":"Hartwig FP, Borges MC, Horta BL, Bowden J et al (2017) Inflammatory biomarkers and risk of schizophrenia: a 2-sample Mendelian randomization study. JAMA Psychiat 74(12):1226\u20131233","journal-title":"JAMA Psychiat"},{"issue":"3","key":"91_CR15","first-page":"CD001257","volume":"19","author":"CB Joy","year":"2006","unstructured":"Joy CB, Mumby-Croft R, Joy LA (2006) Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev 19(3):CD001257","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"91_CR16","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.4088\/JCP.10r06264yel","volume":"71","author":"JM Kane","year":"2010","unstructured":"Kane JM, Correll CU (2010) Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 71(9):1115\u20131124","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"91_CR17","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/jamapsychiatry.2014.1332","volume":"71","author":"GM Khandaker","year":"2014","unstructured":"Khandaker GM, Pearson RM, Zammit S et al (2014) Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA Psychiat 71(10):1121\u20131128","journal-title":"JAMA Psychiat"},{"key":"91_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.bbi.2017.11.020","volume":"69","author":"GM Khandaker","year":"2018","unstructured":"Khandaker GM, Zammit S, Burgess S et al (2018) Association between a functional interleukin 6 receptor genetic variant and risk of depression and psychosis in a population-based birth cohort. Brain Behav Immun 69:264\u2013272","journal-title":"Brain Behav Immun"},{"key":"91_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0165-1781(96)02915-0","volume":"66","author":"M Maes","year":"1997","unstructured":"Maes M, Delange J, Ranjan R et al (1997) Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 66:1\u201311","journal-title":"Psychiatry Res"},{"issue":"1","key":"91_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/jamapsychiatry.2016.2902","volume":"74","author":"PD McGorry","year":"2017","unstructured":"McGorry PD, Nelson B, Markulev C et al (2017) Effect of \u03c9-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: the NEURAPRO randomized clinical trial. JAMA Psychiat 74(1):19\u201327. \nhttps:\/\/doi.org\/10.1001\/jamapsychiatry.2016.2902","journal-title":"JAMA Psychiat"},{"key":"91_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.psc.2016.01.003","volume":"39","author":"BJ Miller","year":"2016","unstructured":"Miller BJ, Buckley PF (2016) The case for adjunctive monoclonal antibody immunotherapy in schizophrenia. Psychiatr Clin N Am 39:187\u2013198","journal-title":"Psychiatr Clin N Am"},{"key":"91_CR22","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","volume":"70","author":"BJ Miller","year":"2011","unstructured":"Miller BJ, Buckley P, Seabolt W et al (2011) Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 70:663\u2013671","journal-title":"Biol Psychiatry"},{"key":"91_CR23","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000356538","volume":"21","author":"N M\u00fcller","year":"2014","unstructured":"M\u00fcller N (2014) Immunology of schizophrenia. Neuroimmunomodulation 21:109\u2013116","journal-title":"Neuroimmunomodulation"},{"key":"91_CR24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.pnpbp.2012.11.008","volume":"42","author":"N M\u00fcller","year":"2013","unstructured":"M\u00fcller N, Myint AM, Krause D et al (2013) Anti-inflammatory treatment in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 42:146\u2013153","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"91_CR25","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/schbul\/sbt070","volume":"6","author":"M Nitta","year":"2013","unstructured":"Nitta M, Kishimoto T, Muller N et al (2013) Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull 6:1230\u20131241","journal-title":"Schizophr Bull"},{"issue":"8","key":"91_CR26","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","volume":"63","author":"S Potvin","year":"2008","unstructured":"Potvin S, Stip E, Sepehry AA et al (2008) Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63(8):801\u2013808","journal-title":"Biol Psychiatry"},{"issue":"1","key":"91_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","volume":"70","author":"CL Raison","year":"2013","unstructured":"Raison CL, Rutherford RE, Woolwine BJ et al (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiat 70(1):31\u201341","journal-title":"JAMA Psychiat"},{"issue":"7","key":"91_CR28","doi-asserted-by":"publisher","first-page":"724","DOI":"10.2174\/1389450111314070002","volume":"14","author":"B Rolland","year":"2013","unstructured":"Rolland B, Deguil J, Jardri R et al (2013) Therapeutic prospects of PPARs in psychiatric disorders: a comprehensive review. Curr Drug Targets 14(7):724\u2013732","journal-title":"Curr Drug Targets"},{"issue":"1","key":"91_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/schbul\/sbt139","volume":"40","author":"IE Sommer","year":"2014","unstructured":"Sommer IE, van Westrhenen R, Begemann MJ et al (2014) Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 40(1):181\u2013191","journal-title":"Schizophr Bull"},{"issue":"4","key":"91_CR30","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3371\/CSRP.5.4.5","volume":"5","author":"EF Torrey","year":"2012","unstructured":"Torrey EF, Davis JM (2012) Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas. Clin Schizophr Relat Psychoses 5(4):208\u2013216","journal-title":"Clin Schizophr Relat Psychoses"}],"container-title":["Current Topics in Behavioral Neurosciences","Neuroinflammation and Schizophrenia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2019_91","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T16:04:24Z","timestamp":1579709064000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/7854_2019_91"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030391409","9783030391416"],"references-count":30,"URL":"https:\/\/doi.org\/10.1007\/7854_2019_91","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"17 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}